Schroder Investment Management Group
ZVRA icon

Schroder Investment Management Group’s Zevra Therapeutics ZVRA Stock Holding History

Schroder Investment Management Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.15M Sell
439,328
-66,705
-13% -$742K ﹤0.01% 753
2026
Q1 		$4.44M Hold
506,033
– – ﹤0.01% 801
2025
Q4 		$4.46M Buy
506,033
+93,486
+23% +$884K ﹤0.01% 766
2025
Q3 		$3.94M Buy
412,547
+97,078
+31% +$974K ﹤0.01% 815
2025
Q2 		$2.78M Buy
+315,469
New +$2.56M ﹤0.01% 865
2016
Q2 		– Sell
-21,419
Closed -$5.14M – 1212
2016
Q1 		$5.14M Hold
21,419
– – 0.01% 691
2015
Q4 		$6.81M Hold
21,419
– – 0.01% 689
2015
Q3 		$6.64M Sell
21,419
-10,969
-34% -$3.36M 0.01% 691
2015
Q2 		$9.52M Buy
+32,388
New +$7.06M 0.02% 650

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Schroder Investment Management Group's ZVRA Position: Q2 2026 in Review

Schroder Investment Management Group reduced its Zevra Therapeutics (ZVRA) stake by 13% in Q2 2026, selling an estimated $742K and leaving 439,328 shares worth $6.15M. The position accounts for ﹤0.01% of the portfolio, ranked #753.

Schroder Investment Management Group first reported a position in ZVRA in Q2 2015 and has held it in 9 quarters since. The position peaked at $9.52M in Q2 2015. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Schroder Investment Management Group held 439,328 shares of Zevra Therapeutics worth $6.15M as of Q2 2026.
  • Schroder Investment Management Group sold 66,705 Zevra Therapeutics shares in Q2 2026, an estimated $742K.
  • Zevra Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #753 holding.
  • Schroder Investment Management Group first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 9 quarters since.
  • Schroder Investment Management Group's Zevra Therapeutics position peaked at $9.52M in Q2 2015.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.